Skip to Content
Merck
  • Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management?

Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management?

Heart (British Cardiac Society) (2013-01-15)
Jocasta Ball, Melinda Jane Carrington, Simon Stewart
ABSTRACT

We examined cognitive function in older hospitalised patients with chronic atrial fibrillation (AF). A prospective substudy of a multicentre randomised trial of an AF-specific disease management intervention (the Standard versus Atrial Fibrillation spEcific managemenT studY; SAFETY). Three tertiary referral hospitals within Australia. A total of 260 patients with chronic AF: mean age 72±11 years, 53% men, mean CHA2DS2-VASc score 4±2. Cognitive function was assessed at baseline (during inpatient stay) using the Montreal Cognitive Assessment (MoCA). The extent of mild cognitive impairment (MCI-defined as a MoCA score <26) in AF patients and identification of independent predictors of MCI. Overall, 169 patients (65%, 95% CI 59% to 71%) were found to have MCI at baseline (mean MoCA score 21±3). Multiple deficits in cognitive domains were identified, most notably in executive functioning, visuospatial abilities and short-term memory. Predictors of MCI (age and sex-adjusted) were lower education level (technical/trade school level OR 6.00, 95% CI 2.07 to 17.42; <8 years school education OR 5.29, 95% CI 1.95 to 14.36 vs 8-13 years), higher CHA2DS2-VASc score (OR 1.46, 95% CI 1.23 to 1.74) and prescribed digoxin (OR 2.19, 95% CI 1.17 to 4.10). MCI is highly prevalent amongst typically older high-risk patients hospitalised with AF. Routine assessment of cognitive function with adjustment of clinical management is indicated for this patient group.

MATERIALS
Product Number
Brand
Product Description

Supelco
Digoxin, analytical standard
Supelco
Digoxin, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Digoxin, European Pharmacopoeia (EP) Reference Standard
Supelco
Digoxin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Digoxin for peak identification, European Pharmacopoeia (EP) Reference Standard